S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
Leukemia
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
The risk of developing any long-term effects depends on the type and dose of treatment that was used and the age at which the patient underwent treatment.
A study of 30 patients who had AML that was in remission for at least 10 years demonstrated a 13% incidence of secondary malignancies.[8] Of 31 female long-term survivors of AML or acute lymphoblastic leukemia (ALL) diagnosed before age 40 years, 26 resumed normal menstruation after completion of therapy. Among 36 live offspring of survivors, two congenital problems occurred.[8]
Most patients with AML who undergo intensive therapy are treated with an anthracycline. Anthracyclines have been associated with increased risk of congestive heart failure (CHF).[9] Anthracycline cardiotoxicity is dose-dependent. In one study, doxorubicin-related CHF was 5% at a lifetime cumulative dose of 400 mg/m2, rising to 26% at a cumulative dose of 550 mg/m2.[10] In many cases, heart failure can manifest as a late effect.[11] In an analysis of children who underwent treatment for acute leukemia, the cumulative incidence of CHF at 10 years was 1.7% in ALL and 7.5% in AML.[12]
Patients who undergo allogeneic hematopoietic stem cell transplant can experience a large number of long-term or late side effects of treatment as a result of high-dose chemotherapy and/or radiation, and as an effect of chronic graft-versus-host disease and immunosuppression. These side effects may include chronic fatigue, thyroid and gonadal dysfunction, infertility, chronic infection, accelerated coronary heart disease, osteopenia, cataracts, iron overload, adverse psychological outcomes, and second cancers.[13-15]
In the Bone Marrow Transplant Survivor Study, hematopoietic cell transplant survivors had accelerated aging and were 8.4 times more likely to be frail than their siblings (95% confidence interval [CI], 2.0−34.5; P = .003). In a multivariable analysis, frailty was associated with a 2.76-fold increase in the risk of death, compared with a nonfrail state (95% CI, 1.7−4.4; P < .001).[16]
Sources: 16
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Therapy-related myeloid neoplasms (t-MN) include AML (t-AML) and MDS (t-MDS) that arise secondary to cytotoxic chemotherapy and/or radiation therapy.[5] The therapy-related (or secondary) MDS are included because of their close clinicopathological relationships to therapy-related AML. Although these therapy-related disorders can be distinguished by the specific mutagenic agents involved, this distinction may be difficult to make because of the frequent overlapping use of multiple potentially mutagenic agents in treating cancer.[68] Because the associated cytogenetic abnormality, not the mutagenetic agent, determines prognosis and treatment it should be noted in the diagnosis.[10]
Since t-MN have been associated with germline pathogenic variants in cancer susceptibility genes, considering germline genetic testing or genetic counseling is warranted in those with strong family histories of cancer.[69]
Sources: 69
Alkylating agent-related t-MN
The alkylating agent/radiation-related acute leukemias and myelodysplastic syndromes typically occur 5 to 6 years after exposure to the mutagenic agent, with a reported range of approximately 10 to 192 months.[70,71] The risk of occurrence is related to both the total cumulative dose of the alkylating agent and the age of the patient.
Cytogenetic abnormalities have been observed in more than 90% of cases of t-MN and commonly include chromosomes 5 and/or 7.[70,72,73] Complex chromosomal abnormalities (≥3 distinct abnormalities) are the most common finding.[68,72-74]
Topoisomerase II inhibitor-related t-MN
Topoisomerase II inhibitor-related t-MN occurs in patients treated with topoisomerase II inhibitors. The agents implicated are the epipodophyllotoxins etoposide and teniposide and the anthracyclines doxorubicin and 4-epi-doxorubicin.[70] The mean latency period from the time of institution of the causative therapy to the development of t-MN is approximately 2 years.[75]
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
The treatment of patients with acute myeloid leukemia (AML) is based on whether the disease is newly diagnosed (previously untreated), in remission, or recurrent. Also, the intensity of the treatment and the patient's overall health status are considered when choosing a treatment approach. Successful treatment of AML requires the control of bone marrow and systemic disease, and specific treatment of central nervous system (CNS) disease, if present. The cornerstone of this strategy includes systemically administered combination chemotherapy. Because only 5% or fewer of patients with AML develop CNS disease, prophylactic treatment is not indicated.[1,2]
Newly diagnosed (untreated): Untreated AML is defined as newly diagnosed leukemia that has not been previously treated. The initial treatment for patients with newly diagnosed AML is often induction therapy that aims to induce a remission. In patients with AML, a complete remission (CR) is defined as a normal peripheral blood cell count (absolute neutrophil count >1,000/mm3 and platelet count >100,000/mm3) and normocellular marrow with less than 5% blasts in the marrow and no signs or symptoms of the disease. In addition, no signs or symptoms are evident of CNS leukemia or other extramedullary infiltration.[3] Modifications to the definition of CR have been proposed because some responses are deeper than a CR, and others may not meet all the criteria for a complete response. In addition, most AML patients meeting the criteria for CR have residual leukemia.[3]
| Response Category | Definition |
|---|---|
| ANC = absolute neutrophil count; CR = complete remission; CRh = CR with partial hematologic recovery; CRi = CR with incomplete hematologic recovery; CRMRD− = CR without measurable residual disease; MLFS = morphological leukemia-free state; PR = partial remission; RT–qPCR = reverse transcription–quantitative polymerase chain reaction. | |
| CRMRD− | If studied pretreatment, CR with negativity for a genetic marker by RT–qPCR, or CR with negativity by multicolor flow cytometry. |
| CR | Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC ≥1.0 × 109/L (1,000/microL); platelet count ≥100 × 109/L (100,000/microL). |
| CRh | ANC ≥0.5 x 109/L (500/microL) and platelet count ≥50 x 109/L (100,000/microL); otherwise all other CR criteria met.[4] |
| CRi | All CR criteria except for residual neutropenia (<1.0 × 109/L [1,000/microL]) or thrombocytopenia (<100 × 109/L [100,000/microL]). |
| MLFS | Bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required. |
| PR | All hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%. |
| No response | Patients evaluable for response but not meeting criteria for CR, CRh, CRi, MLFS, or PR are categorized as having no response prior to the response landmark. Patients failing to achieve response by the designated landmark are designated as having refractory disease. |
Sources: 4
In remission: When patients are in a remission after induction chemotherapy, consolidation chemotherapy is given, with the aim of deepening the response and consolidating the remission. Maintenance therapy is not included in most current treatment protocols and clinical trials. Consolidation therapy appears to be effective when given immediately after remission is achieved.[5]
Sources: 5
Persistent/recurrent disease: Despite intensive chemotherapy, some patients with newly diagnosed AML will not go into remission and have primary refractory disease. Also, some patients who are in a remission after induction and consolidation chemotherapy may have a return of their disease.[3] The rates of primary refractory disease and relapse vary with the age of the patient, genomic variants seen in the leukemia cells, and initial treatment given.
Sources: 3
| Response Category | Definition | |
|---|---|---|
| CR = complete remission; CRh = CR with partial hematologic recovery; CRhMRD-LL = CR with partial hematologic recovery and measurable residual disease at a low level; CRi = CR with incomplete hematologic recovery; CRiMRD-LL = CR with incomplete hematologic recovery and measurable residual disease at a low level; CRMRD- = CR without measurable residual disease; CRMRD-LL = CR with measurable residual disease detection at a low level; MRD = measurable residual disease; MRD- = absence of measurable residual disease; MRD+ = presence of measurable residual disease; MLFS = morphological leukemia-free state; PR = partial response; RT–qPCR = reverse transcription–quantitative polymerase chain reaction. | ||
| Primary refractory disease | No CR, CRh, or CRi at the response landmark (i.e., after two courses of intensive induction treatment) or a defined landmark (e.g., 180 days after commencing less-intensive therapy). | |
| Relapsed disease (after CR, CRh, or CRi) | Bone marrow blasts ≥5%; or reappearance of blasts in the blood in at least two peripheral blood samples obtained at least 1 week apart; or development of extramedullary disease. | |
| MRD relapse (after CR, CRh, or CRi without MRD-) | Defined by one of the following: | |
| Conversion from MRD- to MRD+, independent of method; or | ||
| Increase of MRD copy numbers ≥1 log10 between any two positive samples in patients with CRMRD-LL, CRhMRD-LL, or CRiMRD-LL by qPCR. | ||
| Either result should be rapidly confirmed in a second consecutive sample from the same tissue source. | ||
| Stable disease | Absence of CRMRD-, CR, CRi, PR, MLFS; and criteria for progressive disease not met. | |
| Progressive disease | Evidence for an increase in bone marrow blast percentage and/or increase of absolute blast counts in the blood: | |
| >50% increase in marrow blasts; or | ||
| >50% increase in peripheral blasts in the absence of differentiation syndrome; or | ||
| New extramedullary disease. | ||
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Because myelosuppression is an anticipated consequence of both the leukemia and its treatment with chemotherapy, patients must be closely monitored during therapy. Facilities must be available for hematologic support with multiple blood fractions, including platelet transfusions, and for the treatment of related infectious complications.[6]
Sources: 6
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Supportive care during remission induction treatment should routinely include red blood cell and platelet transfusions, when appropriate.[7,8] Rapid marrow ablation with consequent earlier marrow regeneration decreases morbidity and mortality. Randomized trials have shown similar outcomes for patients who received prophylactic platelet transfusions at a level of 10,000/mm3 rather than 20,000/mm3.[9] The incidence of platelet alloimmunization was similar among groups randomly assigned to receive pooled platelet concentrates from random donors; filtered, pooled platelet concentrates from random donors; ultraviolet B-irradiated, pooled platelet concentrates from random donors; or filtered platelets obtained by apheresis from single random donors.[10]
No good evidence exists to support granulocyte transfusions in the treatment of AML. A multicenter randomized trial (RING [NCT00627393]) was conducted to address the utility of granulocyte transfusions in the setting of infections.[11] There was no difference between the granulocyte and control arms for the composite primary end point of survival plus microbial response at 42 days after randomization. However, the power to detect a true beneficial effect was low because enrollment was half that of the planned study size.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
The following growth factors have been studied in the treatment of AML:
Colony-stimulating factors: Granulocyte colony–stimulating factor and granulocyte-macrophage colony–stimulating factor have been studied in an effort to shorten the period of granulocytopenia associated with leukemia treatment.[12] If used, these agents are administered after administration of chemotherapy. Although the use of growth factors decreases the time to neutrophil recovery by 2 to 5 days, and decreases rates of febrile neutropenia and duration of hospitalization, randomized clinical trials have not shown an impact of growth factors on overall survival and their cost-effectiveness has been inconsistently reported.[13,14] Use of growth factors is not routinely recommended in the remission induction setting.
Erythropoiesis-stimulating agents: Anemia associated with the diagnosis of AML and induction chemotherapy is managed primarily with red blood transfusions. Unlike myelodysplastic syndromes, there is no role for the use of erythropoiesis stimulating agents (e.g., epoetin alfa and darbepoetin) during the treatment of AML.
Thrombopoietin mimetics: Clinical trials have assessed the use of thrombopoietin mimetics in the treatment of AML. Eltrombopag as a single agent was tested in a multicenter, randomized, placebo-controlled, double-blind, phase I/II trial of 98 patients with platelet counts less than 30 × 109/L as a result of AML or MDS. No significant improvements in platelet counts were recorded. Significant hemorrhage was reported in ten (16%) patients given eltrombopag and nine (26%) patients given placebo. No difference in disease progression or overall survival was observed.[15]Eltrombopag appeared to hasten platelet recovery and reduce the number of platelet transfusions needed when added in an unblinded fashion to induction chemotherapy in older FLT3-negative AML patients.[16] However, in a separate, randomized double-blind study of 148 patients, eltrombopag or placebo was added to high-dose induction chemotherapy.[17] The results of this study did not indicate any clinical benefit of eltrombopag over placebo. Given the minimal efficacy signal at this point, eltrombopag is not routinely recommended in the supportive care or remission induction setting.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Empiric broad spectrum antimicrobial therapy is an absolute necessity for febrile patients who are profoundly neutropenic.[18,19] Careful instruction in personal hand hygiene, dental care, and recognition of early signs of infection are appropriate in all patients. Elaborate isolation facilities (including filtered air, sterile food, and gut flora sterilization) are not indicated.[20,21] Likewise, there are no advantages to eating a cooked neutropenic diet, as demonstrated in randomized trials.[22]
Antibiotic prophylaxis with a fluoroquinolone and antifungal prophylaxis with an oral triazole or parenteral echinocandin is appropriate for patients with expected prolonged, profound neutropenia (<100/mm3 for 2 weeks for profound neutropenia lasting >7 days).[23] Unlike patients undergoing treatment for acute lymphoblastic lymphoma, Pneumocystis jirovecii prophylaxis is not routinely employed.
Sources: 23
Nucleoside analog-based antiviral prophylaxis, such as acyclovir, is appropriate for patients who are seropositive for herpes simplex virus undergoing induction chemotherapy.[23]
Sources: 23
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Treatment options for newly diagnosed (untreated; remission induction) acute myeloid leukemia (AML) include:
Chemotherapy.
Sources: Chemotherapy
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Chemotherapy for AML is divided into the following two general categories:
Intensive remission-induction chemotherapy.
Nonintensive chemotherapy.
One of the following combination chemotherapy regimens may be used as intensive remission induction therapy:
Cytarabine plus mitoxantrone.[7]
Sources: 7
Cytarabine plus anthracycline plus midostaurin.[8]
Sources: 8
Cytarabine plus anthracycline plus gemtuzumab ozogamicin.[9]
Sources: 9
Liposomal daunorubicin-cytarabine (CPX-351).[10]
Sources: 10
Intrathecal cytarabine or methotrexate may be used to treat central nervous system (CNS) leukemia, if present.
The two-drug regimen of cytarabine given as a continuous infusion for 7 days and a 3-day course of anthracycline (the so-called 7 + 3 induction therapy) results in a complete response rate of approximately 65%. In most instances, there is no further clinical benefit when adding potentially non-cross−resistant drugs (such as fludarabine, topoisomerase inhibitors, thioguanine, mitoxantrone, histone deacetylases inhibitors, or clofarabine) to a 7 + 3 regimen. Cladribine, when added to 7 + 3 induction chemotherapy, showed improved remission rates [11] and survival rates [12] across two randomized controlled trials, but this regimen has not been widely adopted in the absence of confirmatory trials. The addition of midostaurin and gemtuzumab ozogamicin to intensive induction chemotherapy is discussed below.
The choice of anthracycline and the dose-intensity of anthracycline may influence the survival of patients with AML. Idarubicin appeared to be more effective than daunorubicin, particularly in younger adults, although the doses of idarubicin and daunorubicin may not have been equivalent.[3-6] No significant survival difference between daunorubicin and mitoxantrone has been reported.[13]
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
At present, there is no conclusive evidence to recommend one anthracycline over another.
Evidence (anthracyclines):
In a systematic review and meta-analysis, 18 randomized controlled trials that included 6,755 patients assessed the use of idarubicin versus daunorubicin as part of induction chemotherapy.[14]
Sources: 14
In a systematic review and meta-analysis, 18 randomized controlled trials that included 6,755 patients assessed the use of idarubicin versus daunorubicin as part of induction chemotherapy.[14]
The use of idarubicin led to improved outcomes, including overall survival (OS), when compared with daunorubicin (12 studies, 5,976 patients; hazard ratio [HR], 0.90; 95% confidence interval [CI], 0.84−0.96; P = .0008). However, there was an increased risk of death during induction (14 studies, 6,349 patients; relative risk [RR], 1.18; 95% CI, 1.01−1.36; P = .03) and mucositis (five studies, 2,000 patients; RR, 1.22; 95% CI, 1.04−1.44; P = .02) with idarubicin as compared with daunorubicin. Moreover, the survival benefit for idarubicin was no longer present if a daunorubicin dose of at least 180 mg/m2 was used (four studies, 2,867 patients; HR, 0.91; 95% CI, 0.82−1.00; P = .06).
In patients aged 60 years and younger, outcomes for those who received daunorubicin (90 mg/m2/dose, total induction dosing at 270 mg/m2) were superior to those who received more traditional dosing (45 mg/m2/dose; total dose = 135 mg/m2). The complete remission (CR) rate was 71% versus 57% (P < .001), and the median survival was 24 months versus 16 months (P = .003).[15]
Sources: 15
No randomized comparison data between daunorubicin at 270 mg/m2 and daunorubicin at 180 mg/m2, or between daunorubicin at 270 mg/m2 and idarubicin, are available.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Variants in the tyrosine kinase domain (TKD) and internal tandem duplications (ITD) of the FLT3 gene are frequent in AML and are often associated with an inferior outcome.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (midostaurin):
A multicenter, randomized, phase III trial (NCT00651261) included patients with FLT3-altered AML. Patients received either the FLT3/multikinase inhibitor, midostaurin, or placebo in addition to cytarabine and daunorubicin induction chemotherapy. The addition of midostaurin led to improved survival (median, 75 vs. 26 months; HR for death, 0.78; one-sided P = .009).[8]
Sources: NCT00651261 · 8
A multicenter, randomized, phase III trial (NCT00651261) included patients with FLT3-altered AML. Patients received either the FLT3/multikinase inhibitor, midostaurin, or placebo in addition to cytarabine and daunorubicin induction chemotherapy. The addition of midostaurin led to improved survival (median, 75 vs. 26 months; HR for death, 0.78; one-sided P = .009).[8]
The event-free survival (defined as the time from randomization to relapse, death from any cause, or failure to achieve protocol-specified CR) was improved for patients in the midostaurin arm (HR for event or death, 0.78; one-sided P = .002), and the survival benefit was consistent across all FLT3 variant subtypes. The rates of CR (59% vs. 54%) and time to neutrophil count recovery were similar between the two arms.[8][Level of evidence A1]
Sources: 8 · Level of evidence A1
The U.S. Food and Drug Administration (FDA) approved midostaurin in combination with induction therapy for patients with AML and any FLT3 variant.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (quizartinib):
A multicenter, randomized, phase III trial (NCT02668653) included patients with FLT3-ITD–altered AML. Patients received either the selective ITD-specific FLT3 inhibitor, quizartinib, or placebo in addition to cytarabine and daunorubicin induction chemotherapy. The addition of quizartinib led to improved survival (median, 31.9 vs. 15.1 months; HR for death, 0.78; P = .032).[16]
Sources: NCT02668653 · 16
A multicenter, randomized, phase III trial (NCT02668653) included patients with FLT3-ITD–altered AML. Patients received either the selective ITD-specific FLT3 inhibitor, quizartinib, or placebo in addition to cytarabine and daunorubicin induction chemotherapy. The addition of quizartinib led to improved survival (median, 31.9 vs. 15.1 months; HR for death, 0.78; P = .032).[16]
The EFS (defined as the time from randomization to lack of CR within 42 days from the start of the last induction cycle, relapse, or death from any cause, whichever occurred first) was similar for patients in the quizartinib and placebo arms (HR for event or death, 0.92; 95% CI, 0.75–1.11; P = .24). The rates of CR and time to neutrophil count recovery were similar between the two arms.[16][Level of evidence A1]
Sources: 16 · Level of evidence A1
The FDA approved quizartinib in combination with induction therapy for patients with AML and an FLT3-ITD variant but not for patients with other FLT3 variants, such as FLT3-TKD.
The addition of an FLT3 inhibitor to induction chemotherapy is the standard of care for patients with FLT3-altered AML who are eligible for intensive chemotherapy. An ongoing study (NCT03836209) is evaluating which FLT3 inhibitor is best for patients with FLT3-ITD AML receiving up-front chemotherapy. Additional studies are evaluating FLT3 inhibitors in combination with hypomethylating agents and venetoclax in patients who are not candidates for intensive therapy.
Sources: NCT03836209
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (gemtuzumab ozogamicin):
In a meta-analysis of more than 3,000 patients, the addition of the CD33-directed immunotoxin gemtuzumab ozogamicin to cytarabine plus anthracycline or clofarabine plus anthracycline led to a small increase in the OS rate at 5 years (30.7% vs. 34.6%; HR, 0.90; 95% CI, 0.82−0.98; P = .01).[9] The FDA label for gemtuzumab ozogamicin includes a boxed warning about the risk of hepatotoxicity, including severe or fatal hepatic sinusoidal obstruction syndrome.
Sources: 9
In a meta-analysis of more than 3,000 patients, the addition of the CD33-directed immunotoxin gemtuzumab ozogamicin to cytarabine plus anthracycline or clofarabine plus anthracycline led to a small increase in the OS rate at 5 years (30.7% vs. 34.6%; HR, 0.90; 95% CI, 0.82−0.98; P = .01).[9] The FDA label for gemtuzumab ozogamicin includes a boxed warning about the risk of hepatotoxicity, including severe or fatal hepatic sinusoidal obstruction syndrome.
The improvement in the 5-year OS rate was seen across all ages, but this effect was greatest in patients with favorable-risk cytogenetics (55.2% vs. 76.3%; HR, 0.47; 95% CI, 0.31−0.73; P = .0005), and to a lesser extent with intermediate-risk cytogenetics (34.1% vs. 39.4%; HR, 0.84; 95% CI, 0.75−0.95; P = .007). It was not seen in patients with an adverse-risk karyotype.[9][Level of evidence A1]
Sources: 9 · Level of evidence A1
In contrast, gemtuzumab ozogamicin did not improve the 1-year survival rate of older patients who received low-dose cytarabine, although the CR rate increased from 17% to 30% (odds ratio [OR], 0.48; 95% CI, 0.32–0.73; P = .006).[17]
Sources: 17
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
CPX-351 is a two-drug liposomal encapsulation that delivers cytarabine and daunorubicin at a fixed 5:1 synergistic molar ratio.
Evidence (CPX-351):
A multicenter trial investigated CPX-351 in patients aged 60 to 75 years with therapy-related AML, AML with a history of myelodysplastic syndrome (MDS), or AML with myelodysplasia-related changes.[10]
Sources: 10
A multicenter trial investigated CPX-351 in patients aged 60 to 75 years with therapy-related AML, AML with a history of myelodysplastic syndrome (MDS), or AML with myelodysplasia-related changes.[10]
Compared with 7 + 3 induction chemotherapy, CPX-351 resulted in a better overall remission rate (47.7% vs. 33.3%; P = .016), and improved median OS (9.56 vs. 5.95 months; HR, 0.69; 95% CI, 0.52−0.90; P = .003).[10][Level of evidence A1]
Sources: 10 · Level of evidence A1
The rates of early mortality and toxicities were similar between the two arms. However, the median time to recovery of neutrophils and platelets was longer for CPX-351 (35.0 and 36.5 days, respectively) as compared with 7 + 3 induction chemotherapy (29 and 29 days, respectively).
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Some patients may decline or be too frail for intensive induction chemotherapy. Low-dose cytarabine, decitabine, azacitidine, or best supportive care can be considered equivalently effective treatment approaches for older patients with AML who decline traditional 7 + 3 induction chemotherapy. Unlike a succinct course of 7 + 3 induction, these less-intensive therapies are continued indefinitely, as long as the patient is deriving benefit (i.e., until disease progression or significant toxicity occurs).
One of the following chemotherapy regimens may be used as less-intensive therapy:
Hypomethylating agents (azacitidine and decitabine).
Low-dose cytarabine.
Venetoclax plus hypomethylating agents or low-dose cytarabine.
Glasdegib plus low-dose cytarabine.
Ivosidenib with or without azacitidine.
Enasidenib.
Intrathecal cytarabine or methotrexate may be used to treat CNS leukemia, if present.
Evidence (chemotherapy for patients who decline intensive remission induction therapy):
Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19]
Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19]
Azacitidine: An international phase III trial (NCT01074047) randomly assigned patients with AML who were 65 years or older to receive either azacitidine or conventional regimens (7 + 3 induction, low-dose cytarabine, or best supportive care alone).[20]
Sources: NCT01074047 · 20
Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19] › Azacitidine: An international phase III trial (NCT01074047) randomly assigned patients with AML who were 65 years or older to receive either azacitidine or conventional regimens (7 + 3 induction, low-dose cytarabine, or best supportive care alone).[20]
Azacitidine led to a median OS of 10.4 months (95% CI, 8.0−12.7) as compared with 6.5 months (95% CI, 5.0−8.6) with conventional regimens (HR, 0.85; 95% CI, 0.69−1.03; P = .1009).[20][Level of evidence A1]
Sources: 20 · Level of evidence A1
Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19]
Decitabine: One phase III trial randomly assigned 485 patients with AML who were older than 65 years to receive either decitabine (n = 242) or their preferred choice (n = 243) of either supportive care (n = 28) or low-dose cytarabine (n = 215).[21]Compared with treatment for 5 consecutive days, treatment for 10 consecutive days may lead to higher response rates, particularly in those with TP53 variants and/or unfavorable cytogenetic features.[22][Level of evidence C3]
Sources: 21 · 22 · Level of evidence C3
Hypomethylating agents: The hypomethylating agents azacitidine and decitabine are used commonly in this population of older patients, particularly in the United States. Although approval of the drugs by the FDA is for an MDS indication, the registration studies leading to approval included patients with 20% to 30% myeloblasts, or what would now be considered oligoblastic AML.[18,19] › Decitabine: One phase III trial randomly assigned 485 patients with AML who were older than 65 years to receive either decitabine (n = 242) or their preferred choice (n = 243) of either supportive care (n = 28) or low-dose cytarabine (n = 215).[21]Compared with treatment for 5 consecutive days, treatment for 10 consecutive days may lead to higher response rates, particularly in those with TP53 variants and/or unfavorable cytogenetic features.[22][Level of evidence C3]
Although rates of CR + CRp (CR with incomplete platelet recovery) were more than double in the decitabine arm (17.8%) compared with the treatment-choice arm (7.8%) (P = .001), median OS was not significantly improved for patients receiving decitabine (7.7 months) compared with the treatment of choice (5.0 months) (HR for death for decitabine, 0.85; 95% CI, .69–1.04; P = .11).
Low-dose cytarabine: Older adults who decline intensive remission-induction therapy or are considered ineligible for intensive remission-induction therapy may derive benefit from low-dose cytarabine, administered twice daily for 10 days in cycles repeated every 4 to 6 weeks.[23]
Sources: 23
Low-dose cytarabine: Older adults who decline intensive remission-induction therapy or are considered ineligible for intensive remission-induction therapy may derive benefit from low-dose cytarabine, administered twice daily for 10 days in cycles repeated every 4 to 6 weeks.[23]
The CR rate using this regimen was 18% compared with 1% for patients treated with hydroxyurea (P = .006).
Survival with low-dose cytarabine was better than was survival with hydroxyurea (OR, 0.60; 95% CI, 0.44–0.81; P = .009).[23][Level of evidence A1]
Sources: 23 · Level of evidence A1
Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies.
Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies.
The first study (NCT02203773) was a nonrandomized, open-label, phase Ib clinical trial of venetoclax in combination with azacitidine or decitabine.[24]
Sources: NCT02203773 · 24
Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies. › The first study (NCT02203773) was a nonrandomized, open-label, phase Ib clinical trial of venetoclax in combination with azacitidine or decitabine.[24]
In this study, 35 (61%; 95% CI, 47.6%−74.0%) of 57 patients had CR or CR with incomplete hematologic recovery (CRi). The median duration of response for all patients with a response (CR + CRi + partial remission [PR]) was 8.4 months (range, 4.7−11.7; n = 36).
Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies.
The second study (NCT02287233) was a phase I/IIb study of venetoclax in combination with low-dose cytarabine in 82 patients with newly diagnosed AML, including patients with previous exposure to a hypomethylating agent for an antecedent hematologic disorder such as MDS.[25]
Sources: NCT02287233 · 25
Venetoclax plus hypomethylating agents or low-dose cytarabine: The FDA approved venetoclax, an inhibitor of the anti-apoptotic protein BCL2, in combination with low-dose cytarabine or a hypomethylating agent for the treatment of AML in patients aged 75 years or older, and those who cannot undergo 7 + 3 induction chemotherapy because of comorbidities. Approval was granted based on the results of two studies. › The second study (NCT02287233) was a phase I/IIb study of venetoclax in combination with low-dose cytarabine in 82 patients with newly diagnosed AML, including patients with previous exposure to a hypomethylating agent for an antecedent hematologic disorder such as MDS.[25]
In the 82 patients enrolled in the study, the CR/CRi rate was 54% (95% CI, 42%−65%), with a median duration of remission of 8.1 months (95% CI, 5.3−14.9 months). The median OS for all patients, irrespective of response, was 10.1 months (95% CI, 5.7−14.2 months).
The most common adverse events with venetoclax combinations are gastrointestinal symptoms and myelosuppression, which may require delays between cycles, growth factor support, or decreased duration of venetoclax administration per cycle. Additionally, appropriate prophylactic measures are typically taken to prevent tumor lysis syndrome.[25][Level of evidence C3]
Sources: 25 · Level of evidence C3
Glasdegib plus low-dose cytarabine: Glasdegib, an oral inhibitor of the hedgehog pathway, combined with low-dose cytarabine was compared with low-dose cytarabine alone in a randomized, phase II open-label study that included 116 patients with AML who were aged 75 years or older or who had severe comorbid conditions (cardiac disease, renal impairment, or Eastern Cooperative Oncology Group performance status 2).[26] Similar to venetoclax, the FDA approved glasdegib in combination with low-dose cytarabine for the treatment of AML in patients aged 75 years or older or who are unable to receive intensive induction chemotherapy.
Sources: 26
Glasdegib plus low-dose cytarabine: Glasdegib, an oral inhibitor of the hedgehog pathway, combined with low-dose cytarabine was compared with low-dose cytarabine alone in a randomized, phase II open-label study that included 116 patients with AML who were aged 75 years or older or who had severe comorbid conditions (cardiac disease, renal impairment, or Eastern Cooperative Oncology Group performance status 2).[26] Similar to venetoclax, the FDA approved glasdegib in combination with low-dose cytarabine for the treatment of AML in patients aged 75 years or older or who are unable to receive intensive induction chemotherapy.
Of the 78 patients with AML who received glasdegib plus low-dose cytarabine, 24% (n = 19) of patients had a CR or CRi compared with 5% (2 of 38) of patients who received low-dose cytarabine alone. The median OS was 8.3 months (80%; CI, 6.6–9.5) for patients who received glasdegib/low-dose cytarabine and 4.3 months (80%; CI, 2.9–4.9) for patients who received low-dose cytarabine alone in patients with AML (HR, 0.46; 80% CI, 0.35–0.62; P = .0002).[26][Level of evidence A1]
Sources: 26 · Level of evidence A1
Ivosidenib: For older or frail patients with AML and IDH1 variants, the IDH1 inhibitor ivosidenib is an option. The FDA approved ivosidenib alone or in combination with azacitidine for the treatment of AML that has a susceptible IDH1 variant (detected by an FDA-approved diagnostic test) in adults aged 75 years or older with newly diagnosed AML or who have comorbidities that preclude the use of intensive induction chemotherapy. Within the context of a phase I study, 34 patients with newly diagnosed IDH1-altered AML who were not candidates for intensive induction chemotherapy were treated with single-agent ivosidenib.[27]The combination of azacitidine and ivosidenib was evaluated in a double-blind, randomized, placebo-controlled, phase III trial in patients with newly diagnosed AML who were not eligible for intensive induction chemotherapy. The intention-to-treat analysis included 72 patients treated with azacitidine and ivosidenib and 74 patients treated with azacitidine and placebo. A supplemental new drug application for ivosidenib in combination with azacitidine for patients with untreated IDH1-altered AML is under priority review with the FDA.[28]
Ivosidenib: For older or frail patients with AML and IDH1 variants, the IDH1 inhibitor ivosidenib is an option. The FDA approved ivosidenib alone or in combination with azacitidine for the treatment of AML that has a susceptible IDH1 variant (detected by an FDA-approved diagnostic test) in adults aged 75 years or older with newly diagnosed AML or who have comorbidities that preclude the use of intensive induction chemotherapy. Within the context of a phase I study, 34 patients with newly diagnosed IDH1-altered AML who were not candidates for intensive induction chemotherapy were treated with single-agent ivosidenib.[27]The combination of azacitidine and ivosidenib was evaluated in a double-blind, randomized, placebo-controlled, phase III trial in patients with newly diagnosed AML who were not eligible for intensive induction chemotherapy. The intention-to-treat analysis included 72 patients treated with azacitidine and ivosidenib and 74 patients treated with azacitidine and placebo. A supplemental new drug application for ivosidenib in combination with azacitidine for patients with untreated IDH1-altered AML is under priority review with the FDA.[28]
Differentiation syndrome was reported in 6 patients (18%), but did not require treatment discontinuation.
The rate of CR plus CRi was 42.4% (95% CI, 25.5%−60.8%), with a median duration of response that was not reached (lower bound of the 95% CI was 4.6 months).
For all 34 patients on the study, the median OS was 12.6 months (95% CI, 4.5−25.7).[27][Level of evidence C3]
Sources: 27 · Level of evidence C3
At a median follow-up of 12.4 months, the primary end point of EFS was improved in patients who received azacitidine and ivosidenib, compared with patients who received azacitidine and placebo (HR, 0.33; 95% CI, 0.16–0.69).
The median OS was 24 months for patients who received azacitidine and ivosidenib and 7.9 months for patients who received azacitidine and placebo (HR for death, 0.44; 95% CI, 0.27–0.73).
Differentiation syndrome occurred in 14% of patients who received azacitidine and ivosidenib and 8% of patients who received azacitidine and placebo. The incidence of bleeding events was 41% with azacitidine and ivosidenib and 29% with azacitidine and placebo. Infection of any grade was seen in 28% of patients who received azacitidine and ivosidenib and 49% of patients who received azacitidine and placebo. For more information about differentiation syndrome, see the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia section.[28][Level of evidence A1]
Sources: Treatment of Newly Diagnosed Acute Promyelocytic Leukemia · 28 · Level of evidence A1
Enasidenib: For patients with AML and IDH2 variants, the IDH2 inhibitor enasidenib is an option for older or frail patients. Although it does not have approval in this setting, enasidenib monotherapy was evaluated in a phase I/II trial in patients with newly diagnosed AML who were not eligible for standard chemotherapy.[29]
Sources: 29
Enasidenib: For patients with AML and IDH2 variants, the IDH2 inhibitor enasidenib is an option for older or frail patients. Although it does not have approval in this setting, enasidenib monotherapy was evaluated in a phase I/II trial in patients with newly diagnosed AML who were not eligible for standard chemotherapy.[29]
Of the 39 patients enrolled, seven (18%) had CR, one (3%) had CRi, and two (5%) had a PR.
Median OS for all patients was 11.3 months (95% CI, 5.7−15.1), and was not reached for patients who had a response.[29][Level of evidence C3]
Sources: 29 · Level of evidence C3
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Although individual patients with acute myeloid leukemia (AML) have been reported to have long disease-free survival (DFS) or cure with a single cycle of chemotherapy,[1] consolidation therapy is always indicated in therapy that is planned with curative intent. In a small randomized study conducted by the Eastern Cooperative Oncology Group, all patients who did not receive consolidation therapy experienced a relapse after a short median complete remission (CR) duration.[2]
Treatment options for AML in remission (consolidation phase) include:
Chemotherapy with short-term (3−4 cycles), relatively intensive chemotherapy with cytarabine-based regimens similar to standard induction clinical trials (consolidation chemotherapy) and consolidation chemotherapy with more dose-intensive cytarabine-based treatment.
Sources: Chemotherapy
Maintenance therapy (longer-term therapy at lower doses) has not been shown to benefit AML patients in a number of studies, but two strategies have shown a benefit:
Sources: Maintenance therapy
Maintenance therapy (longer-term therapy at lower doses) has not been shown to benefit AML patients in a number of studies, but two strategies have shown a benefit:
Midostaurin in patients with FLT3-altered AML.
Sources: Midostaurin
Oral azacitidine.
Sources: Oral azacitidine
Hematopoietic cell (bone marrow or stem cell) transplant.
Sources: Hematopoietic cell (bone marrow or stem cell) transplant
Hematopoietic cell (bone marrow or stem cell) transplant.
High-dose chemotherapy with autologous peripheral blood stem cell rescue.
High-dose marrow-ablative or reduced-intensity therapy followed by allogeneic hematopoietic cell transplant (HCT).
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Nontransplant consolidation therapy using cytarabine-containing regimens has treatment-related death rates that are usually less than 10% to 20% and has reported long-term DFS rates from 20% to 50%.[3-6] The optimal doses, schedules, and duration of consolidation chemotherapy have not been determined.
The standard consolidation therapy for AML patients in remission is high-dose cytarabine; however, there exists some controversy about whether it benefits all younger AML patients in first complete response versus selected subgroups, such as those with core-binding factor abnormalities.[7-11] The duration of consolidation therapy has ranged from one cycle [4,6] to four or more cycles.[3,5]
Evidence (chemotherapy):
A large, randomized trial that compared three different cytarabine-containing consolidation therapy regimens showed a clear benefit in survival to patients younger than 60 years who received high-dose cytarabine.[3]
Sources: 3
Intensification of cytarabine dose or duration of consolidation chemotherapy with conventionally dosed cytarabine did not improve DFS or overall survival (OS) in patients aged 60 years or older, as evidenced in the Medical Research Council (MRC-LEUK-AML11) trial.[12,13]
Dose-intensive cytarabine-based chemotherapy can be complicated by severe neurological [14] and/or pulmonary toxic effects [15] and should be administered by physicians experienced in these regimens at centers that are equipped to treat potential complications. In a retrospective analysis of 256 patients who received high-dose bolus cytarabine at a single institution, the most powerful predictor of cytarabine neurotoxicity was renal insufficiency. The incidence of neurotoxicity was significantly greater in patients treated with twice daily doses of 3 g/m2/dose when compared with 2 g/m2/dose.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
While a number of older studies have included longer-term therapy at lower doses (maintenance), there has been no convincing evidence that maintenance therapy provides prolonged DFS or OS. However, maintenance therapy with midostaurin or oral azacitidine may improve outcomes.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (midostaurin):
Variants in the tyrosine kinase domain and internal tandem duplications of the FLT3 gene are frequent in AML and are often associated with an inferior outcome.
In the multicenter, randomized, phase III RATIFY trial (NCT00651261), the FLT3/multikinase inhibitor midostaurin plus cytarabine and daunorubicin induction chemotherapy was compared with placebo in patients with FLT3-altered AML.[16][Level of evidence A1]While maintenance was well tolerated in the RATIFY study, only a small subset of patients tolerated midostaurin as maintenance therapy after chemotherapy or transplant in a separate phase II study.[18]
Sources: RATIFY · 16 · Level of evidence A1 · 18
In the multicenter, randomized, phase III RATIFY trial (NCT00651261), the FLT3/multikinase inhibitor midostaurin plus cytarabine and daunorubicin induction chemotherapy was compared with placebo in patients with FLT3-altered AML.[16][Level of evidence A1]While maintenance was well tolerated in the RATIFY study, only a small subset of patients tolerated midostaurin as maintenance therapy after chemotherapy or transplant in a separate phase II study.[18]
The addition of the FLT3/multikinase inhibitor midostaurin to cytarabine and daunorubicin induction chemotherapy led to improved survival (median, 75 vs. 26 months; hazard ratio [HR] for death, 0.78; one-sided P = .009).
Patients who remained in remission after completion of consolidation therapy entered a maintenance phase in which they received midostaurin or placebo, administered at a dose of 50 mg orally twice daily, for twelve 28-day cycles. A maintenance regimen was administered for the full 12 cycles in 120 patients (69 in the midostaurin group, and 51 in the placebo group).
An ad-hoc landmark analysis from the end of maintenance revealed no difference in DFS between the two arms. Moreover, from the start of maintenance therapy there was no difference in OS between the two arms.[17]
Sources: 17
In the multicenter, randomized phase II RADIUS trial (NCT01883362), the addition of midostaurin to standard of care was compared with standard of care alone after allogeneic HCT.[19] Similar to the RATIFY trial, midostaurin was administered at a dose of 50 mg orally twice daily, for twelve 28-day cycles. Thirty patients were enrolled in each arm, but only half were able to complete the entire 12 cycles of therapy.
In the multicenter, randomized phase II RADIUS trial (NCT01883362), the addition of midostaurin to standard of care was compared with standard of care alone after allogeneic HCT.[19] Similar to the RATIFY trial, midostaurin was administered at a dose of 50 mg orally twice daily, for twelve 28-day cycles. Thirty patients were enrolled in each arm, but only half were able to complete the entire 12 cycles of therapy.
The estimated 18-month relapse-free survival (RFS) rate was 89% in the midostaurin arm and 76% in the standard of care arm (HR, 0.46; 95% confidence interval [CI], 0.12−1.86; P = 0.27). The predicted relative reduction in the risk of relapse with the addition of midostaurin was 54%.[19][Level of evidence B1]
Sources: 19 · Level of evidence B1
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (oral azacitidine):
The randomized, double-blind, placebo-controlled phase III QUAZAR AML-001 trial (NCT01757535) provided the basis for regulatory approval of oral azacitidine as maintenance therapy for AML.[20] The study included 472 patients with AML who were aged 55 years or older, were within 4 months of first CR or CR with incomplete hematologic recovery after induction chemotherapy with or without consolidation treatment, and were not candidates for allogeneic HCT. Oral azacitidine or placebo was administered at 300 mg daily for 14 days every 28 days. Treatment was continued until disease progression or unacceptable toxicity.
Sources: QUAZAR AML-001 · 20
The randomized, double-blind, placebo-controlled phase III QUAZAR AML-001 trial (NCT01757535) provided the basis for regulatory approval of oral azacitidine as maintenance therapy for AML.[20] The study included 472 patients with AML who were aged 55 years or older, were within 4 months of first CR or CR with incomplete hematologic recovery after induction chemotherapy with or without consolidation treatment, and were not candidates for allogeneic HCT. Oral azacitidine or placebo was administered at 300 mg daily for 14 days every 28 days. Treatment was continued until disease progression or unacceptable toxicity.
For patients who received azacitidine, the median OS from randomization was 24.7 months (95% CI, 18.7−30.5) compared with 14.8 months (95% CI, 11.7−17.6) for patients receiving placebo (HR, 0.69; 95% CI, 0.55−0.86; P = .0009).[20][Level of evidence A1]
Sources: 20 · Level of evidence A1
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Allogeneic HCT, even with minimal conditioning chemotherapy, results in the lowest incidence of leukemic relapse, even when compared with HCT from an identical twin (syngeneic HCT). This finding led to the concept of an immunologic graft-versus-leukemia effect, similar to (and related to) graft-versus-host disease. The improvement in freedom from relapse using allogeneic HCT as the primary consolidation therapy is offset, at least in part, by the increased morbidity and mortality caused by graft-versus-host disease, veno-occlusive disease of the liver, and infection. The DFS rates using allogeneic transplant in first complete remission have ranged from 45% to 60%.[21-24]
The use of allogeneic HCT in adults requires either a HLA-matched sibling donor, an HLA-matched unrelated donor, a haploidentical donor (“half HLA-matched”), or two well-matched umbilical cord blood units. Including patients who underwent HCT from 2007 to 2017, the 3-year probabilities of survival after HLA-matched sibling transplant were 59% (±1%) for patients with early disease, 53% (±1%) for patients with intermediate disease, and 29% (±1%) for patients with advanced disease, according to the Center for International Blood and Marrow Transplant Research registry.[24] The probabilities of survival after an unrelated donor transplant were 53% (±1%) for patients with early disease, 50% (±1%) for intermediate disease, and 27% (±1%) for patients with advanced disease. [Level of evidence C1]
Sources: 24 · Level of evidence C1
Because HCT can cure more than 30% of patients who experience relapse after chemotherapy, some investigators suggested that allogeneic bone marrow transplant (BMT) can be reserved for early first relapse or second CR without compromising the number of patients who are ultimately cured.[25] Clinical and cytogenetic information can define certain subsets of patients with predictable better or worse prognoses according to favorable- and adverse-risk factors in those using consolidation chemotherapy.[26]
Favorable-risk AML: Favorable-risk factors include t(8;21), inv(16), normal karyotype with an NPM1 variant (in absence of an FLT3 variant), and normal karyotype with double cytosine-cytosine-adenosine-adenosine-thymidine (CCAAT)-enhancer binding protein (C/EBP)-alpha variants. Patients in the favorable-risk group have a reasonable chance of cure with intensive consolidation chemotherapy, and it may be reasonable to defer transplant in that group until early first relapse.
Adverse-risk AML: Adverse-risk factors include deletion of 5q, 7q, 17p, inversion of 3 or t(3;3), abnormality of (17p), trisomy 8, t(6;9), t(9;22), most translocations involving chromosome 11q23, KMT2A variants, a complex or monosomal karyotype, a history of myelodysplasia or antecedent hematologic disorder, TP53 variants, RUNX1 variants, ASXL1 variants, and normal karyotype with FLT3 variants. The adverse-risk group is highly unlikely to be cured with consolidation chemotherapy, and allogeneic BMT in first CR is a reasonable option for patients. However, even with allogeneic stem cell transplant, the outcome for patients with high-risk AML is poor (5-year DFS rate of 8% to 30% for patients with treatment-related leukemia or myelodysplasia).[27]
Sources: 27
Normal cytogenetics: Patients with normal cytogenetics are in an intermediate-risk group, and consolidation management should be individualized based on additional molecular markers, patient comorbid factors, and patient preference or, preferably, managed according to a clinical trial.
A common clinical trial design used to evaluate the benefit of allogeneic transplant as consolidation therapy for AML in first remission is the so-called donor-no donor comparison. In this design, newly diagnosed AML patients who achieve a CR are deemed medically eligible for allogeneic transplant and undergo HLA typing. If a matched sibling or matched unrelated donor is identified, the patient is allocated to the transplant arm. Analysis of outcome is by intention to treat; that is, patients assigned to the donor arm who do not receive a transplant are grouped in the analysis with the patients who did actually receive a transplant. RFS is the usual end point for this type of trial. OS from the time of diagnosis is less frequently reported in these trials.
Investigators attempted to address this issue with a meta-analysis using data from 18 separate prospective trials of AML patients using the donor-no donor design, with data from an additional six trials included for sensitivity analysis.[28] The trials included in this meta-analysis enrolled adult patients aged 60 years and younger from 1982 to 2006. Median follow-up ranged from 42 months to 142 months. Preparative regimens were similar among the different trials. Allogeneic transplant was compared with autologous transplant (six trials) or with a variety of consolidation chemotherapy regimens, with high-dose cytarabine being the most common.
Sources: 28
Treatment-related mortality ranged from 5% to 42% in the donor groups compared with 3% to 27% in the no-donor group.
Of 18 trials reporting RFS across all cytogenetic risk groups, the combined HR for overall RFS benefit with allogeneic transplant was 0.80, indicating a statistically significant reduction in death or relapse in a first CR.
Of the 15 trials reporting OS across all cytogenetic risk groups, the combined HR for OS was 0.90, again indicating a statistically significant reduction in death or relapse in a first CR.
In subgroup analysis according to cytogenetic risk , there was no RFS or OS benefit of allogeneic transplant for patients with favorable-risk AML (RFS: HR, 1.07; 95% CI, 0.83–1.38; P = .59; OS: HR, 1.06; 95% CI, 0.64–1.76; P = .81). However, a transplant benefit was seen for patients with intermediate (RFS: HR, 0.83; 95% CI, 0.74–0.93; P < .01; OS: HR, 0.84; 95% CI, 0.71–0.99; P = .03) or adverse-risk cytogenetics (RFS: HR, 0.73; 95% CI, 0.59–0.90; P < .01; OS: HR, 0.60; 95% CI, 0.40–0.90; P = .01).[28][Level of evidence B4] The conclusion from this meta-analysis was that allogeneic transplant from a sibling donor in a first CR is justified on the basis of improved RFS and OS for patients with intermediate- or adverse-risk, but not favorable-risk, cytogenetics.An important caveat to this analysis is that induction and consolidation strategies for AML among studies included in the meta-analysis were not uniform; nor were definitions of cytogenetic risk groups uniform. This may have resulted in inferior survival rates among chemotherapy-only treated patients.
Sources: 28 · Level of evidence B4
Most physicians who treat patients with leukemia agree that transplant should be offered to AML patients in first CR in the setting of adverse-risk cytogenetics and should not be offered to patients in first CR with favorable-risk cytogenetics.[26] However, older patients with favorable-risk AML who are unlikely to tolerate intensive cytarabine-based consolidation therapy can be considered for allogeneic HCT as consolidation therapy.[29]
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
The role of autologous transplant for AML patients has diminished over time because of the improvements in the nonrelapse mortality associated with allogeneic HCT, as well as the advent of haploidentical and umbilical cord transplant expanding the potential donor pool so that nearly every patient has a donor.[30-33] Autologous HCT can yield DFS rates between 35% and 50% in patients with AML in first remission. Autologous HCT has also cured a smaller proportion of patients in second remission.[34-40] Treatment-related mortality rates of patients who have had autologous peripheral blood or marrow transplant range from 10% to 20%.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
No standard treatment regimen exists for patients with refractory or recurrent acute myeloid leukemia (AML).[1,2]
Treatment options for refractory or recurrent AML include:
Chemotherapy.
Sources: Chemotherapy
Reduced-intensity therapy, including targeted therapy.
Sources: Reduced-intensity therapy, including targeted therapy
Allogeneic hematopoietic cell transplant (HCT).
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
A number of intensive salvage chemotherapy regimens have demonstrated efficacy in recurrent AML, including:
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
FLAG has shown antileukemic activity in patients with relapsed and refractory AML.
Evidence (FLAG):
A multicenter phase II study included 83 patients with relapsed or refractory AML or de novo refractory anemia with excess blasts in transformation. The primary end point was the rate of complete remission (CR) achieved after one or two courses of FLAG induction chemotherapy.[3]
Sources: 3
A multicenter phase II study included 83 patients with relapsed or refractory AML or de novo refractory anemia with excess blasts in transformation. The primary end point was the rate of complete remission (CR) achieved after one or two courses of FLAG induction chemotherapy.[3]
In patients with relapsed leukemia whose first remission lasted for 6 months or more, the CR rate was 81% (17 of 21 patients).
In patients with AML whose first remission lasted less than 6 months, or in patients with primary refractory disease, the CR rate was 30% (13 of 44 patients).[3][Level of evidence C3]
Sources: 3 · Level of evidence C3
Myelosuppression and mucositis were common therapy-related toxicities.
Idarubicin has been added to this regimen as well (FLAG-Ida).[4]
Sources: 4
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (MEC):
A study evaluated one course of MEC chemotherapy in 74 patients with AML and a poor prognosis. The population included 30 patients with relapsed AML, 28 patients with primary refractory AML, and 16 patients with secondary AML.[5]
Sources: 5
A study evaluated one course of MEC chemotherapy in 74 patients with AML and a poor prognosis. The population included 30 patients with relapsed AML, 28 patients with primary refractory AML, and 16 patients with secondary AML.[5]
MEC demonstrated a CR induction rate of 55%.[5][Level of evidence C3]
Sources: 5 · Level of evidence C3
A phase III randomized Eastern Cooperative Oncology Group (ECOG) trial (E-2995) assessed 129 patients with one of the following disease statuses: relapsed AML less than 6 months after first CR; relapsed AML after allogeneic or autologous bone marrow transplant; second or greater AML relapse; primary induction failure; secondary AML; or high-risk myelodysplastic syndromes. Patients were randomly assigned to receive MEC with or without valspodar, a multidrug resistance modulator.
A phase III randomized Eastern Cooperative Oncology Group (ECOG) trial (E-2995) assessed 129 patients with one of the following disease statuses: relapsed AML less than 6 months after first CR; relapsed AML after allogeneic or autologous bone marrow transplant; second or greater AML relapse; primary induction failure; secondary AML; or high-risk myelodysplastic syndromes. Patients were randomly assigned to receive MEC with or without valspodar, a multidrug resistance modulator.
The complete response rate was only 17% to 25% in both arms.[6][Level of evidence B3]
Sources: 6 · Level of evidence B3
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (standard or high-dose cytarabine and mitoxantrone):
A study of cytarabine and mitoxantrone included 49 patients with relapsed or refractory AML.[7]
Sources: 7
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (high-dose etoposide and cyclophosphamide):
Reported results have been similar to those for the combination of cytarabine and mitoxantrone.[9]
Sources: 9
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Patients who are unable or unwilling to undergo intensive therapy can be treated with reduced-intensity therapies.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Gilteritinib is an oral FLT3 inhibitor with activity in both internal tandem duplication (ITD) and tyrosine kinase domain (TKD) subtypes.
Evidence (gilteritinib):
In a phase III trial, 371 patients were randomly assigned in a 2:1 ratio to receive either gilteritinib or preselected salvage chemotherapy (MEC, FLAG-Ida, azacitidine, or low-dose cytarabine).[16,17]
In a phase III trial, 371 patients were randomly assigned in a 2:1 ratio to receive either gilteritinib or preselected salvage chemotherapy (MEC, FLAG-Ida, azacitidine, or low-dose cytarabine).[16,17]
With a median follow-up of 37.1 months, the median overall survival (OS) was 9.3 months for patients who received gilteritinib versus 5.6 months for patients who received chemotherapy (hazard ratio [HR] for death, 0.665; 95% confidence interval [CI], 0.52–0.85). The estimated OS rate at 2 years was 20.6% (95% CI, 15.8%–26.0%) for patients who received gilteritinib and 14.2% (95% CI, 8.3%–21.6%) for patients who received chemotherapy.[16] Among those treated with gilteritinib, the median duration of complete response or complete response with partial hematologic recovery was 10 months (interquartile range [IQR], 2.08–not evaluable), and 23 months (IQR, 4.9–not evaluable) for just those achieving a complete response.[17]
The rates of complete response and complete response with partial hematologic recovery were higher in patients who received gilteritinib than in patients who received chemotherapy (34% vs. 15.3%; HR, 18.6; 95% CI, 9.8–27.4).
Adverse events of grade 3 or higher were less common in patients who received gilteritinib when adjusted for exposure time.[16][Level of evidence A1] The most common adverse event of interest was increased liver transaminases for patients who received gilteritinib therapy. If liver transaminase levels (considered related to treatment) increase to more than 5 times the upper limit of normal, gilteritinib therapy is paused. When the enzymes return to less than 2.5 times the upper limit of normal, therapy can resume at a reduced dose of 80 mg once daily.[17][Level of evidence A1]
Sources: 16 · Level of evidence A1 · 17 · Level of evidence A1
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Enasidenib is an oral small molecule inhibitor with activity against the altered IDH2 enzyme.
Evidence (enasidenib):
In a phase I/II study, 214 patients with relapsed or refractory AML were treated with enasidenib.[18]
Sources: 18
In a phase I/II study, 214 patients with relapsed or refractory AML were treated with enasidenib.[18]
The overall response rate was 40.3% (95% CI, 33.0%–48.0%), with a median response duration of 5.8 months.
This included 46 patients (26.1%) with a CR or a CR with incomplete hematologic recovery (CRi).
Grade 3 or 4 treatment-related adverse events included indirect hyperbilirubinemia (12%) and differentiation syndrome (7%). As a result, the U.S. Food and Drug Administration (FDA) added a boxed warning to enasidenib, which alerts prescribers that differentiation syndrome can occur.[18][Level of evidence C3]
Sources: boxed warning · 18 · Level of evidence C3
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Ivosidenib is an oral small molecule inhibitor with activity against the altered IDH1 enzyme.
Evidence (ivosidenib):
In a phase I/II study, 179 patients with relapsed or refractory AML were treated with ivosidenib.[19]
Sources: 19
In a phase I/II study, 179 patients with relapsed or refractory AML were treated with ivosidenib.[19]
The overall response rate was 39.1% (95% CI, 31.9%–46.7%) with a median duration response of 6.5 months (range, 4.6–9.3). This included 54 patients (30.2%) with a CR or a CRi.
Over one-third of patients who initially required transfusions became transfusion independent.
Grade 3 or higher prolongation of the QT interval was seen in 14 patients (7.8%), and grade 3 or higher differentiation was seen in 7 patients (3.9%). The FDA added a boxed warning to ivosidenib, which alerts prescribers that differentiation syndrome can occur.[19][Level of evidence C3]
Sources: boxed warning · 19 · Level of evidence C3
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Revumenib is an oral menin inhibitor that is approved by the FDA for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients aged 1 year and older.
In the phase I/II AUGMENT-101 study (NCT04065399), 104 patients with relapsed or refractory acute leukemia with a KMT2A rearrangement received revumenib. Patients had to have a corrected QT interval (QTc) using Fridericia's formula of less than 450 milliseconds at baseline.[20]
Sources: AUGMENT-101 · 20
In the phase I/II AUGMENT-101 study (NCT04065399), 104 patients with relapsed or refractory acute leukemia with a KMT2A rearrangement received revumenib. Patients had to have a corrected QT interval (QTc) using Fridericia's formula of less than 450 milliseconds at baseline.[20]
The overall rate of CR plus CRh (complete remission with partial hematologic recovery) was 21.2% (95% CI, 13.8%–30.3%). The median duration of CR plus CRh was 6.4 months (95% CI, 2.7–not reached).[20][Level of evidence C3]
Sources: 20 · Level of evidence C3
Of the 83 patients who were dependent on red blood cell and/or platelet transfusions, 14% became independent of transfusions during a 56-day postbaseline period.
Revumenib has a boxed warning for differentiation syndrome, which was observed in 29% of patients. Grade 3 or 4 differentiation syndrome was observed in 13% of patients, and one patient died (0.7%).
Sources: boxed warning
Grade 3 or higher QTc prolongation was observed in 12% of patients.
Because revumenib is metabolized by CYP3A4, the dose must be reduced in patients receiving strong CYP3A4 inhibitors. The standard dose for patients who weigh more than 40 kg is 270 mg orally twice daily, with a dose reduction to 160 mg orally twice daily for patients receiving a strong CYP3A4 inhibitor. Furthermore, the dose is adjusted according to body surface area in patients who weigh less than 40 kg.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (hypomethylating agents):
In a retrospective analysis, 655 patients with relapsed or primary treatment-refractory AML received either azacitidine (57%) or decitabine (43%).[21]
Sources: 21
In a retrospective analysis, 655 patients with relapsed or primary treatment-refractory AML received either azacitidine (57%) or decitabine (43%).[21]
Overall, 16% of patients achieved a CR or a CRi and experienced a median OS of 21 months.[21][Level of evidence C3]
Sources: 21 · Level of evidence C3
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
The antibody-targeted chemotherapy agent gemtuzumab ozogamicin has been evaluated in patients who had relapsed AML and expressed CD33.
Evidence (gemtuzumab ozogamicin):
A pooled analysis of three open-label, single-arm, phase II studies included 277 patients.[22]
Sources: 22
A pooled analysis of three open-label, single-arm, phase II studies included 277 patients.[22]
The overall response rate was 26%. Thirty-five patients (13%) achieved a CR and 36 patients (13%) achieved a CR without platelet recovery. It is unclear whether the inadequate platelet recovery was the result of megakaryocyte toxic effects of gemtuzumab or subclinical residual leukemia. [22]
Sources: 22
The long-term outcomes of patients who receive gemtuzumab and achieve CR without platelet recovery are unclear. Gemtuzumab induces profound bone marrow aplasia similar to leukemia induction chemotherapy and also has substantial hepatic toxic effects, including hepatic veno-occlusive disease.[22][Level of evidence C3]
Sources: 22 · Level of evidence C3
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (clofarabine with or without cytarabine):
Clofarabine, a purine nucleoside analogue, was studied as a single agent in 62 patients with relapsed or refractory AML.[23]
Sources: 23
Clofarabine, a purine nucleoside analogue, was studied as a single agent in 62 patients with relapsed or refractory AML.[23]
Eight of 19 patients who received treatment for their first relapse experienced a complete response.
Clofarabine was administered in combination with intermediate-dose cytarabine in patients with relapsed or refractory AML.[24]
Sources: 24
Clofarabine was administered in combination with intermediate-dose cytarabine in patients with relapsed or refractory AML.[24]
Seven of 29 patients with AML or myelodysplastic syndrome who received treatment for their first relapse had a CR.[24][Level of evidence C3]
Sources: 24 · Level of evidence C3
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
When patients with relapsed disease are treated aggressively, they may have extended disease-free survival (DFS); however, patients with relapsed disease can only be cured with HCT.[25][Level of evidence C2] Allogeneic HCT for patients in their second CR provides better DFS rates than transplant for patients in relapse.[26][Level of evidence C1]
Sources: 25 · Level of evidence C2 · 26 · Level of evidence C1
Evidence (allogeneic HCT):
Current transplant outcomes are reported by the Center for International Blood and Marrow Transplantation Registry. The group reported the following outcomes for transplants done in the United States between 2008 and 2018:[27][Level of evidence C2]
Sources: 27 · Level of evidence C2
Current transplant outcomes are reported by the Center for International Blood and Marrow Transplantation Registry. The group reported the following outcomes for transplants done in the United States between 2008 and 2018:[27][Level of evidence C2]
The 3-year survival rate was 53% for patients with AML in second or subsequent CR versus 31% for patients with relapsed disease (or never in a CR) who underwent a matched sibling donor transplant.
The 3-year survival rate was 50% for patients with AML in second or subsequent CR versus 30% for patients with relapsed disease (or who never achieved CR) who underwent a matched unrelated donor transplant.
Allogeneic HCT can be effective salvage therapy in some patients whose disease fails to go into remission with intensive chemotherapy (primary refractory leukemia). A number of retrospective studies have demonstrated the ability of allogeneic HCT to induce remission in primary refractory disease.[28]
Sources: 28
Evidence (allogeneic HCT to induce remission):
In one retrospective analysis of 168 patients with AML and primary refractory disease who underwent allogeneic HCT, the 5-year OS rate was 22%.[29]
Sources: 29
Another analysis was conducted among patients enrolled in a prospective cooperative group trial, SWOG S0106 (NCT00085709).[30]
Sources: SWOG S0106 · 30
Another analysis was conducted among patients enrolled in a prospective cooperative group trial, SWOG S0106 (NCT00085709).[30]
Of the 589 patients treated in the cooperative group trial, 150 (25%) had primary refractory disease.
Among the 64 patients with primary refractory disease who received an allogeneic HCT, the 4-year survival rate was 48% compared with 4% among the 86 patients who did not undergo transplant.[30][Level of evidence C3]
Sources: 30 · Level of evidence C3
Randomized trials testing the efficacy of this approach are not available.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Special consideration must be given to induction therapy for APL. Treatment is centered around the use of differentiating agents to clear the leukemic cells. Early mortality is related to bleeding, differentiation syndrome, or infection. High complete remission (CR) rates are very common across treatment regimens, and persistent disease or relapse is rare.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Treatment options for newly diagnosed APL include:
All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) for low- to intermediate-risk disease.
Sources: All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) for low- to intermediate-risk disease
ATRA plus chemotherapy, followed by ATO-based consolidation therapy for high-risk disease.
Sources: ATRA plus chemotherapy, followed by ATO-based consolidation therapy for high-risk disease
ATRA induces terminal differentiation of the leukemic cells followed by restoration of nonclonal hematopoiesis. Administration of ATRA leads to rapid resolution of coagulopathy in most patients, and heparin administration is not required in patients receiving ATRA. However, randomized trials have not shown a reduction in morbidity and mortality during ATRA induction when compared with chemotherapy. ATRA administration may result in the following conditions:
Differentiation syndrome: Administration of ATRA can lead to a syndrome of respiratory distress, known as differentiation syndrome. Prompt recognition of the syndrome and aggressive administration of steroids can prevent severe respiratory distress.[1]
Sources: 1
Hyperleukocytosis: The optimal management of ATRA-induced hyperleukocytosis has not been established. Hyperleukocytosis in APL is typically treated with the addition of cytotoxic chemotherapy. Leukopheresis is not recommended because of an increased risk of complications such as bleeding events and disseminated intravascular coagulation.
Studies performed in the 1990s demonstrated that overall survival (OS) rates improved in patients receiving ATRA in addition to chemotherapy.[2,3] ATO, an agent with both differentiation-inducing and apoptosis-inducing properties against APL cells, is also used in the treatment of APL. Induction remission therapy for APL is determined by disease risk. Low- to intermediate-risk APL (white blood cell [WBC] count ≤10 × 109/L) is treated without chemotherapy (ATRA and ATO), and high-risk is treated with a combination of ATRA and ATO plus chemotherapy.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Evidence (ATRA plus ATO for low- to intermediate-risk disease):
In a phase III, randomized controlled, multicenter trial in patients with APL classified as low-to-intermediate risk (WBC count, ≤10 × 109/L) ATRA plus chemotherapy was compared with ATRA plus ATO.[4]
Sources: 4
In a phase III, randomized controlled, multicenter trial in patients with APL classified as low-to-intermediate risk (WBC count, ≤10 × 109/L) ATRA plus chemotherapy was compared with ATRA plus ATO.[4]
CR rates were equally high for both groups. CR occurred in all 77 patients (100%) who could be evaluated in the ATRA plus ATO group and in 75 of 79 patients (95%) in the ATRA plus chemotherapy group (P = .12).
With a median follow-up of 34.4 months, the 2-year OS rate was 99% (95% confidence interval [CI], 96%−100%) in the ATRA plus ATO group, and 91% (95% CI, 85%−97%) in the ATRA plus chemotherapy group (P = .02).
The 2-year cumulative incidence of relapse was similarly low in both groups, 1% (95% CI, 0%−4%) in the ATRA plus ATO group and 6% (95% CI, 0%−11%) in the ATRA plus chemotherapy group (P = .24).
The primary end point was event-free survival (EFS) (defined as no achievement of hematologic CR after induction therapy, no achievement of molecular CR after three consolidation courses, molecular relapse, hematologic relapse, or death). The 2-year EFS rate was 97% for the ATRA plus ATO group and 85% in the ATRA plus chemotherapy group (P < .001 for noninferiority).
The results of this chemotherapy-free regimen for low- to intermediate-risk APL were confirmed in a second, phase III, randomized controlled trial.[5][Level of evidence A1]
Sources: 5 · Level of evidence A1
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Remission induction with a combination of anthracycline and ATRA is used for remission induction in patients with high-risk disease (WBC count, >10 × 109/L).
Evidence (ATRA plus chemotherapy, followed by ATO-based consolidation therapy for high-risk disease):
The AIDA-2000 study (NCT00180128) combined oral ATRA until CR or for a maximum of 45 days and four doses of intravenous idarubicin (12 mg/m2) on days 2, 4, 6, and 8. Consolidation was then risk stratified so low- to intermediate-risk patients received additional cycles of anthracycline and ATRA, and high-risk patients also received cytarabine, etoposide, 6-thioguanine, and CHT chemotherapy (6-mercaptopurine plus methotrexate) as consolidation.[6]
The AIDA-2000 study (NCT00180128) combined oral ATRA until CR or for a maximum of 45 days and four doses of intravenous idarubicin (12 mg/m2) on days 2, 4, 6, and 8. Consolidation was then risk stratified so low- to intermediate-risk patients received additional cycles of anthracycline and ATRA, and high-risk patients also received cytarabine, etoposide, 6-thioguanine, and CHT chemotherapy (6-mercaptopurine plus methotrexate) as consolidation.[6]
After induction, 420 of 445 patients (94.4%) treated on the AIDA-2000 protocol were in CR. The 6-year OS rate was 87.4% and the cumulative incidence of relapse rate was 10.7%.[6][Level of evidence B4]
Sources: 6 · Level of evidence B4
In the phase II APML4 study, ATO was added to the ATRA-and-idarubicin remission−induction backbone.[7] An ATO-based regimen, which includes gemtuzumab ozogamicin as the only cytotoxic drug, has been developed.
Sources: 7
In the phase II APML4 study, ATO was added to the ATRA-and-idarubicin remission−induction backbone.[7] An ATO-based regimen, which includes gemtuzumab ozogamicin as the only cytotoxic drug, has been developed.
Of the 124 patients who could be evaluated, there were 4 (3.2%) early deaths and 118 (95%) hematologic CRs.
The 2-year freedom-from-relapse rate was 97.5% (95% CI, 90.4%−99.4%), the failure-free survival rate was 88.1% (95% CI, 80.7%−92.8%), and the OS rate was 93.2% (95% CI, 85.8%−96.8%).[7][Level of evidence B4]
Sources: 7 · Level of evidence B4
In a single-institution study, patients received ATRA plus ATO induction. They also received a dose of gemtuzumab ozogamicin (or idarubicin) if the WBC was greater than 10 × 109/L on presentation or rose to more than 30 × 109/L during induction.[8] Patients in remission received ATO and ATRA in alternating months for a total of seven cycles as consolidation; gemtuzumab ozogamicin was substituted if either ATO or ATRA were discontinued because of toxicity. Long-term follow up from this study has been published.[9]
In a single-institution study, patients received ATRA plus ATO induction. They also received a dose of gemtuzumab ozogamicin (or idarubicin) if the WBC was greater than 10 × 109/L on presentation or rose to more than 30 × 109/L during induction.[8] Patients in remission received ATO and ATRA in alternating months for a total of seven cycles as consolidation; gemtuzumab ozogamicin was substituted if either ATO or ATRA were discontinued because of toxicity. Long-term follow up from this study has been published.[9]
Of the 54 patients with high-risk disease treated on the protocol, one patient received both gemtuzumab ozogamicin and idarubicin (12 mg/m2 daily for 3 days) because of persistent leukocytosis despite receiving gemtuzumab ozogamicin.
The CR rate was 96%, and five (9%) patients relapsed.
The 5-year rates were 81% for EFS, 89% for disease-free survival (DFS), and 86% for OS, indicating that the responses are durable.
Across the entire study population, the 5-year OS rate was similar among the 45 high-risk patients who received gemtuzumab ozogamicin (84%) compared with the seven patients who received a dose of idarubicin (100%, P = .453).[8][Level of evidence B4]
Sources: 8 · Level of evidence B4
It is important to note that most current regimens for the treatment of APL include some form of maintenance therapy. A meta-analysis of randomized trials has indicated that maintenance clearly improves DFS but not OS; however, these trials did not include ATO-containing regimens.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Treatment options for recurrent APL include:
ATO with or without chemotherapy.
Sources: ATO with or without chemotherapy
Hematopoietic cell transplant (HCT).
Sources: Hematopoietic cell transplant (HCT)
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
ATO has high rates of second remission in patients with relapsed APL.[10] As a single agent, ATO can lead to complete response rates of 80% to 90% in patients with hematologic relapse, and 70% to 80% in patients with molecular remission.[11-14] The choice of salvage therapy is based on the previous therapy and interval of time between first remission and relapse.
In patients with early relapse less than 6 months after ATRA and ATO, anthracycline-based regimens and ATRA as given for initial remission induction for high-risk disease should be considered.
In patients who relapse less than 6 months after ATRA and anthracycline-based regimens (no previous ATO exposure), ATO-based regimens should be considered.
In all patients with late relapse (>6 months), ATO-based regimens with or without anthracycline or gemtuzumab ozogamicin should be considered.
For patients receiving ATO as salvage therapy, a small randomized trial suggested that the addition of ATRA does not confer any benefit over ATO alone in patients who previously received ATRA.[14] In this 20-patient study, the complete response rate after one cycle of ATO with or without ATRA was 80%.
Sources: 14
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025. Captured 2026-09-09.
Some patients in second remission with ATO have experienced long-term DFS after autologous stem cell transplant,[15,16] and it can be considered in patients who are in molecular remission (negative quantitative polymerase chain reaction [PCR] on a marrow sample). Patients who do not go into remission or have evidence of measurable residual disease by quantitative PCR on a marrow sample after salvage therapy are considered for an allogeneic HCT.[17] A registry study reported a 3-year OS rate after transplant in second CR of 80% compared with 59% in patients without transplant (P = .03).[10]
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
AML is caused by certain changes to the way blood stem cells function, especially how they grow and divide into new cells. A risk factor is anything that increases the chance of getting a disease. Some risk factors for AML, like smoking, can be changed. However, risk factors also include things people cannot change, like their genetics, getting older, and their health history.
There are many risk factors for AML, but many do not directly cause cancer. Instead, they increase the chance of DNA damage in cells that may lead to AML. Learn more about how cancer develops at What Is Cancer?
Sources: DNA · What Is Cancer?
Having one or more of these risk factors does not mean that you will get AML. Many people with risk factors never develop AML, while others with no known risk factors do.
Possible risk factors for AML include:
being male
older age
smoking
having had treatment with chemotherapy or radiation therapy in the past
Sources: chemotherapy · radiation therapy
being exposed to radiation in the environment (such as nuclear radiation) or to the chemical benzene
having a personal history of a blood disorder such as myelodysplastic syndrome
Sources: personal history · myelodysplastic syndrome
Talk with your doctor if you think you may be at risk.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
The prognosis and treatment options for AML depend on:
Sources: prognosis
the person's age
whether the leukemia has spread to the CNS
whether the patient has a very high white blood cell count at the time of diagnosis
the subtype of AML
whether the patient received chemotherapy or radiation therapy in the past to treat a different cancer
whether there is a history of a blood disorder such as myelodysplastic syndrome
whether the cancer has been treated before or recurred (come back)
Sources: recurred
It is important to treat AML right away. Older age at diagnosis may be linked to lower remission rates and more complications.
Sources: remission · complications
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
There are different types of treatment for people with acute myeloid leukemia (AML).
The treatment of AML usually has two phases.
Patients receive supportive care for side effects of treatment.
The following types of treatment are used:
The following types of treatment are used:
Chemotherapy
Radiation therapy
Chemotherapy with stem cell transplant
Targeted therapy
Other drug therapy
New types of treatment are being tested in clinical trials.
Treatment for acute myeloid leukemia may cause side effects.
Follow-up care may be needed.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Different types of treatments are available for people with AML. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the phase of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.
Talking with your cancer care team before treatment begins about what to expect will be helpful. You'll want to learn what you need to do before treatment begins, how you'll feel while going through it, and what kind of help you will need. Learn more at Questions to Ask Your Doctor about Treatment.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
There are two treatment phases of AML:
Remission induction therapy is the first phase of treatment. The goal is to kill the leukemia cells in the blood and bone marrow. This puts the leukemia into remission.
Sources: Remission induction therapy · leukemia cells · bone marrow · remission
Consolidation therapy is the second phase of treatment. It begins after the leukemia is in remission. The goal of consolidation therapy is to kill any remaining leukemia cells that may not be active but could begin to regrow and cause a relapse. This phase is also called remission continuation therapy.
Sources: Consolidation therapy · relapse
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Patients must be closely monitored during treatment of AML. Myelosuppression, a condition which results in fewer red blood cells, white blood cells, and platelets, is a side effect of both AML and treatment with chemotherapy. Supportive care during remission induction therapy may include:
Sources: Myelosuppression · red blood cells · white blood cells · platelets · side effect · chemotherapy · Supportive care
red blood cell and platelet transfusions to replace blood cells destroyed by the cancer or its treatment
Sources: transfusions
antibiotics and antifungals to prevent or treat infections
Sources: antibiotics · antifungals · infections
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. The way the chemotherapy is given depends on the subtype of AML being treated and whether the leukemia cells have spread to the central nervous system (CNS; brain and spinal cord).
Sources: subtype
Systemic chemotherapy is when chemotherapy drugs are taken by mouth or injected into a vein or muscle. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body.
Sources: injected
Systemic chemotherapy drugs used to treat AML include:
azacitidine
Sources: azacitidine
cytarabine
Sources: cytarabine
daunorubicin
Sources: daunorubicin
daunorubicin and cytarabine
Sources: daunorubicin and cytarabine
decitabine
Sources: decitabine
idarubicin
Sources: idarubicin
midostaurin
Sources: midostaurin
mitoxantrone
Sources: mitoxantrone
Combinations of these drugs may be used. Other chemotherapy drugs not listed here may also be used.
Intrathecal chemotherapy may be used to treat AML that has spread to the CNS (brain and spinal cord). Intrathecal chemotherapy is a method of placing chemotherapy directly into the cerebrospinal fluid, which is the fluid that surrounds the brain and spinal cord. This approach is used because the blood-brain barrier, a protective layer around the brain, can prevent chemotherapy drugs given by mouth or into a vein from reaching the CNS.
Cytarabine and methotrexate are two chemotherapy drugs given as intrathecal chemotherapy to treat AML. These drugs can also be given systemically.
Sources: methotrexate
Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.
Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. AML is sometimes treated with external radiation therapy. This type of radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Total-body irradiation sends radiation toward the whole body. It is a type of external radiation that may be used to prepare the body for a stem cell transplant when the leukemia has recurred.
Sources: x-rays · radiation · external radiation therapy · Total-body irradiation · stem cell transplant · recurred
Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy and/or total-body irradiation, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: Stem cells · bone marrow · donor · infusion
Learn more about Stem Cell Transplants in Cancer Treatment.
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Targeted therapy uses drugs or other substances to identify and attack specific cancer cells. Your doctor may suggest biomarker tests to help predict your response to certain targeted therapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Sources: biomarker tests · Biomarker Testing for Cancer Treatment
Targeted therapies used to treat AML include:
gemtuzumab ozogamicin
Sources: gemtuzumab ozogamicin
midostaurin
Sources: midostaurin
quizartinib
Sources: quizartinib
revumenib
Sources: revumenib
Less-intensive targeted therapies in people who are unable or unwilling to receive other treatments include:
enasidenib
Sources: enasidenib
gilteritinib
Sources: gilteritinib
glasdegib
Sources: glasdegib
ivosidenib
Sources: ivosidenib
venetoclax
Sources: venetoclax
Learn more about Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Arsenic trioxide and all-trans retinoic acid (ATRA) are anticancer drugs that kill leukemia cells, stop the leukemia cells from dividing, or help the leukemia cells mature into white blood cells. These drugs are used in the treatment of a subtype of AML called acute promyelocytic leukemia.
Sources: Arsenic trioxide · all-trans retinoic acid · acute promyelocytic leukemia
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Standard treatment of untreated acute myeloid leukemia (AML) during the remission induction phase depends on the subtype of AML and may include:
Sources: Standard treatment · remission induction · subtype
combination chemotherapy that includes cytarabine
Sources: combination chemotherapy · cytarabine
combination chemotherapy with targeted therapy (midostaurin or quizartinib), for people whose AML has a mutation in the FLT3 gene
Sources: targeted therapy · midostaurin · quizartinib · mutation · FLT3 gene
combination chemotherapy with the targeted therapy drug gemtuzumab ozogamicin
Sources: gemtuzumab ozogamicin
intrathecal chemotherapy (cytarabine or methotrexate), for central nervous system (CNS) leukemia
Sources: intrathecal chemotherapy · methotrexate · central nervous system
supportive care
Sources: supportive care
For older adults or people who are unable or unwilling to receive intensive chemotherapy, the following may be continued as long as the person benefits or until toxic effects occur:
Sources: intensive chemotherapy · toxic
targeted therapy (enasidenib, gilteritinib, glasdegib, ivosidenib, or venetoclax)
Sources: enasidenib · gilteritinib · glasdegib · ivosidenib · venetoclax)
low-dose chemotherapy (azacitidine, low-dose cytarabine, or decitabine)
Sources: low-dose chemotherapy · azacitidine · cytarabine · decitabine
targeted therapy with low-dose chemotherapy
intrathecal chemotherapy, for CNS leukemia
supportive care
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of acute myeloid leukemia (AML) during the remission phase depends on the subtype of AML and may include:
combination chemotherapy that includes cytarabine
Sources: combination chemotherapy · cytarabine
maintenance therapy with midostaurin, for people whose AML has a mutation in the FLT3 gene
Sources: maintenance therapy · midostaurin · mutation · FLT3 gene
maintenance therapy with chemotherapy
Sources: chemotherapy
high-dose chemotherapy and stem cell transplant using the patient's stem cells
Sources: high-dose chemotherapy · stem cell transplant · stem cells
high-dose chemotherapy, with or without radiation therapy, or reduced-intensity therapy, followed by a stem cell transplant using donor stem cells
Sources: donor
Learn more about these treatments in Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
There is no standard treatment for refractory or recurrent acute myeloid leukemia (AML). Treatment depends on the subtype of AML and may include:
Sources: standard treatment · refractory · recurrent · subtype
combination chemotherapy
Sources: combination chemotherapy
targeted therapy with enasidenib, gemtuzumab ozogamicin, gilteritinib, ivosidenib, or revumenib
Sources: targeted therapy · enasidenib · gemtuzumab ozogamicin · gilteritinib · ivosidenib · revumenib
stem cell transplant using donor stem cells
Sources: stem cell transplant · donor · stem cells
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of newly diagnosed acute promyelocytic leukemia (APL) may include:
Sources: acute promyelocytic leukemia
all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO), for low-risk to intermediate-risk disease
Sources: all-trans retinoic acid · arsenic trioxide · low-risk
ATRA plus combination chemotherapy, followed by ATO, for high-risk disease
Sources: combination chemotherapy · high-risk
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of recurrent acute promyelocytic leukemia (APL) may include:
Sources: recurrent · acute promyelocytic leukemia
arsenic trioxide (ATO) with or without chemotherapy
Sources: arsenic trioxide · chemotherapy
stem cell transplant using the patient's stem cells or donor stem cells
Sources: stem cell transplant · stem cells · donor
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Leukemia
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordLeukemia, Promyelocytic, Acute
ClinicalTrials.gov recordNeutropenia, Infection
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordTuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
ClinicalTrials.gov recordAcute Myeloid Leukemia, Myelodysplastic Syndrome
ClinicalTrials.gov recordAcute Myeloid Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia
ClinicalTrials.gov recordHigh Risk Acute Myeloid Leukemia
ClinicalTrials.gov recordLeukemia, Myeloid, Acute
ClinicalTrials.gov recordAcute Myeloid Leukemia
ClinicalTrials.gov recordHematologic Neoplasms
ClinicalTrials.gov recordRelapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
ClinicalTrials.gov recordBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML)
ClinicalTrials.gov recordAcute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
ClinicalTrials.gov recordAcute Myelogenous Leukemia, AML
ClinicalTrials.gov recordAcute Myeloid Leukemia, Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
ClinicalTrials.gov recordAcute Myeloid Leukemia (AML)
ClinicalTrials.gov recordAcute Myeloid Leukemia (AML)
ClinicalTrials.gov recordNewly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
ClinicalTrials.gov recordMyelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
ClinicalTrials.gov recordBlastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
ClinicalTrials.gov recordAcute Myeloid Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
ClinicalTrials.gov recordAdvanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia,...
ClinicalTrials.gov recordAcute Myeloid Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related...
ClinicalTrials.gov recordMyelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordLymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma, Myelodysplastic Syndrome
ClinicalTrials.gov recordAdult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0),...
ClinicalTrials.gov recordMyelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordCancer
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia
ClinicalTrials.gov recordMyelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia,...
ClinicalTrials.gov recordAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22);...
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Hemophagocytic Lymphohistiocytosis (HLH),...
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission,...
ClinicalTrials.gov recordAdult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic...
ClinicalTrials.gov recordAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, CD45-Positive...
ClinicalTrials.gov recordCancer
ClinicalTrials.gov recordNon-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Indolent...
ClinicalTrials.gov recordAnemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome
ClinicalTrials.gov recordMyelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
ClinicalTrials.gov recordBlood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
ClinicalTrials.gov recordAML, ALL, Undifferentiated Leukemia, Biphenotypic Leukemia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia,...
ClinicalTrials.gov recordAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid...
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordChronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory...
ClinicalTrials.gov recordMultiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
ClinicalTrials.gov recordMultiple Myeloma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Chronic Myeloid Leukemia
ClinicalTrials.gov recordChronic Myelomonocytic Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Multiple Myeloma, Lymphocytic Leukemia, Myeloproliferative...
ClinicalTrials.gov recordLeukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Diseases, Non-Hodgkins Lymphoma,...
ClinicalTrials.gov recordAcute Myeloid Leukemia
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid...
ClinicalTrials.gov recordAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With...
ClinicalTrials.gov recordAdult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordMyelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordMyelomonocytic Leukemia
ClinicalTrials.gov recordChronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia...
ClinicalTrials.gov recordAdult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia...
ClinicalTrials.gov recordMyelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)
ClinicalTrials.gov recordAcute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With...
ClinicalTrials.gov recordAdult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia...
ClinicalTrials.gov recordAdult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission,...
ClinicalTrials.gov recordFLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic...
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm,...
ClinicalTrials.gov recordNeoplasms
ClinicalTrials.gov recordChronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm,...
ClinicalTrials.gov recordLeukemia
ClinicalTrials.gov recordAcute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Mixed Phenotype...
ClinicalTrials.gov recordAML, CMML, MDS
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic...
ClinicalTrials.gov recordMyelofibrosis, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordMyelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordAcute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic...
ClinicalTrials.gov recordAML, MDS, CMML
ClinicalTrials.gov recordLeukemia, Acute Myeloid Leukemia
ClinicalTrials.gov recordChronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome,...
ClinicalTrials.gov recordRelapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
ClinicalTrials.gov recordAcute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia,...
ClinicalTrials.gov recordMyelodysplastic Syndrome, Effects of Chemotherapy, Mild Cognitive Impairment, Multiple Myeloma, Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoid Leukemia,...
ClinicalTrials.gov recordLeukemia, Myelomonocytic, Chronic
ClinicalTrials.gov recordAcute Myeloid Leukemia (AML)
ClinicalTrials.gov recordAcute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of Peripheral Blood White Cells, Chronic...
ClinicalTrials.gov recordMyelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in...
ClinicalTrials.gov recordAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid...
ClinicalTrials.gov recordAcute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential...
ClinicalTrials.gov recordAcute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome,...
ClinicalTrials.gov recordMultiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
ClinicalTrials.gov recordAcute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin,...
ClinicalTrials.gov recordNeoplasms
ClinicalTrials.gov recordAcute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle...
ClinicalTrials.gov recordChronic Myelomonocytic Leukemia, Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Lymphocytic Leukemia, B-cell Lymphoma, T-cell Lymphoma, Non Hodgkin Lymphoma, Hodgkin...
ClinicalTrials.gov recordAcute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile...
ClinicalTrials.gov recordAcute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Myelofibrosis
ClinicalTrials.gov recordAcute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)
ClinicalTrials.gov recordAcute Myeloid Leukemia, Multiple Myeloma
ClinicalTrials.gov recordAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic Syndrome, Myeloproliferative Neoplasm,...
ClinicalTrials.gov recordAcute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic...
ClinicalTrials.gov recordChronic Myelomonocytic Leukemia (CMML)
ClinicalTrials.gov recordRecurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic...
ClinicalTrials.gov recordHematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent...
ClinicalTrials.gov recordAcute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic...
ClinicalTrials.gov recordAcute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordAcute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordRelapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordHematologic Malignancy, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Lymphoma, Leukemia, Myeloma
ClinicalTrials.gov recordMyelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordHigher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordLeukemia, Leukemia, Myeloid, Monocytic Leukemia
ClinicalTrials.gov recordLymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
ClinicalTrials.gov recordMyeloid Neoplasm
ClinicalTrials.gov recordRelapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
ClinicalTrials.gov recordAcute Biphenotypic Leukemia
Acute Leukemia of Ambiguous Lineage
Acute Myeloid Leukemia
Treatment of Newly Diagnosed AML
Treatment of Untreated Acute Myeloid Leukemia
Acute Myeloid Leukemia with inv(3)(q21.3;q26.2); GATA2, MECOM
Acute Undifferentiated Leukemia
Blastic Plasmacytoid Dendritic Cell Neoplasm
Chemotherapy-Related Leukemia
1 INDICATIONS AND USAGE IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as...
KOMZIFTI is a menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment...
Lymphoid Leukemia
Mast Cell Leukemia
Mixed Phenotype Acute Leukemia
1.2 Relapsed or Refractory CD33-positive AML MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.
ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi)...
Prolymphocytic Leukemia
Treatment of Refractory or Recurrent AML
REVUFORJ is indicated for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 ( NPM1 ) mutation [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) , and Clinical Studies...
1 INDICATIONS AND USAGE Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1...
REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
1.1 Acute Myeloid Leukemia RYDAPT is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia...
T-Cell Large Granular Lymphocyte Leukemia
1.1 Newly Diagnosed Acute Myeloid Leukemia TIBSOVO is indicated in combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)...
1 INDICATIONS AND USAGE TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In...
1.2 Relapsed or Refractory Acute Myeloid Leukemia TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as...
1 INDICATIONS AND USAGE VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of...
1 INDICATIONS AND USAGE XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
1.1 Relapsed or Refractory Acute Myeloid Leukemia XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an...
INDICATIONS AND USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each...
DailyMed labelINDICATIONS AND USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each...
DailyMed labelINDICATIONS AND USAGE THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each...
DailyMed labelDAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction...
DailyMed labelINDICATIONS AND USAGE Elliotts B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma.
DailyMed labelFILKRI is a leukocyte growth factor indicated to Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...
DailyMed labelGRAFAPEX is an alkylating drug indicated for: Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of age and older with...
DailyMed labelIDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated for the treatment...
DailyMed labelIDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved...
DailyMed labelINQOVI is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor, indicated: For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and...
DailyMed labelKOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage...
DailyMed labelLEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult...
DailyMed labelMYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: • treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older ( 1.1 ). • treatment of...
DailyMed labelNEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...
DailyMed labelNIVESTYM is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...
DailyMed labelNYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...
DailyMed labelNYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a...
DailyMed labelONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction...
DailyMed labelRELEUKO is a leukocyte growth factor indicated to: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti- cancer drugs associated with a...
DailyMed labelREVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and pediatric patients...
DailyMed labelRelapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected...
DailyMed labelRYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine...
DailyMed labelTIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or...
DailyMed labelVANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly...
DailyMed labelVYXEOS is indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. VYXEOS is a liposomal...
DailyMed labelXOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. ( 1.1 ) 1.1 Relapsed or Refractory Acute...
DailyMed labelZARXIO is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a...
DailyMed label